CareDx Inc (CDNA)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $4.09B
Last updated: Nov 17, 2026 at 11:04 AM ET
CareDx Inc (CDNA) Earnings: Report Dates and Results
CareDx (CDNA) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, CareDx reported EPS of $0.70, above the $0.07 estimate. It beat the EPS estimate in 7 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
CDNA has an expected report date of Feb 22, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 208.3% above the $0.12 reported for the quarter ended Dec 31, 2025.
CDNA Earnings Call
The latest CDNA earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 37 quarters below that had an estimate, CDNA beat 28 and missed 9. The widest gap in the table came in the quarter ended Sep 30, 2026, when EPS landed 900.00% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.70 | $0.07 | N/A | +900.00% | Beat | +150.0% | 6 | 5 up, 0 down | Oct 29, 2026 | N/A |
| Jun 30, 2026 | $0.37 | $0.06 | N/A | +516.67% | Beat | +270.0% | 5 | 1 up, 0 down | Jul 30, 2026 | $263.90M |
| Mar 31, 2026 | $0.34 | $0.13 | $0.11 - $0.15 | +161.54% | Beat | +240.0% | 5 | 0 up, 4 down | Apr 28, 2026 | $117.70M |
| Dec 31, 2025 | $0.12 | -$0.01 | N/A | N/A | N/A | -33.3% | 6 | 1 up, 0 down | Feb 24, 2026 | $108.39M |
| Sep 30, 2025 | $0.28 | $0.14 | $0.12 - $0.17 | +100.00% | Beat | +100.0% | 6 | 1 up, 3 down | Nov 4, 2025 | $100.06M |
| Jun 30, 2025 | $0.10 | $0.12 | $0.10 - $0.14 | -16.67% | Miss | -60.0% | 5 | 1 up, 4 down | Aug 6, 2025 | $86.68M |
| Mar 31, 2025 | $0.10 | $0.07 | $0.06 - $0.09 | +42.86% | Beat | N/A | 6 | 1 up, 3 down | Apr 30, 2025 | $84.69M |
| Dec 31, 2024 | $0.18 | $0.15 | $0.07 - $0.18 | +22.03% | Beat | N/A | 4 | 2 up, 0 down | Feb 26, 2025 | $86.58M |
| Sep 30, 2024 | $0.14 | $0.01 | -$0.02 - $0.06 | N/A | N/A | N/A | 6 | 3 up, 0 down | Nov 4, 2024 | $82.88M |
| Jun 30, 2024 | $0.25 | -$0.14 | -$0.21 - -$0.12 | +278.57% | Beat | N/A | 5 | 1 up, 0 down | Jul 31, 2024 | $92.27M |
| Mar 31, 2024 | -$0.03 | -$0.21 | -$0.28 - -$0.17 | +85.71% | Beat | N/A | 5 | 0 up, 1 down | May 9, 2024 | $72.05M |
| Dec 31, 2023 | -$0.17 | -$0.27 | -$0.29 - -$0.24 | +37.04% | Beat | N/A | 5 | 1 up, 0 down | Feb 28, 2024 | $65.57M |
| Sep 30, 2023 | -$0.18 | -$0.40 | -$0.48 - -$0.35 | +55.00% | Beat | N/A | 5 | 0 up, 1 down | Nov 8, 2023 | $67.19M |
| Jun 30, 2023 | -$0.18 | -$0.31 | -$0.57 - -$0.07 | +41.94% | Beat | N/A | 5 | 0 up, 0 down | Aug 8, 2023 | $70.30M |
| Mar 31, 2023 | -$0.11 | -$0.10 | -$0.21 - -$0.05 | -10.00% | Miss | N/A | 5 | 0 up, 0 down | May 10, 2023 | $77.26M |
| Dec 31, 2022 | -$0.07 | -$0.09 | -$0.13 - -$0.02 | +22.22% | Beat | N/A | 5 | 0 up, 0 down | Feb 27, 2023 | $82.38M |
| Sep 30, 2022 | -$0.06 | -$0.14 | -$0.19 - -$0.09 | +57.14% | Beat | -185.7% | 5 | 0 up, 1 down | Nov 3, 2022 | $79.36M |
| Jun 30, 2022 | -$0.13 | -$0.11 | -$0.16 - -$0.07 | -18.18% | Miss | -218.2% | 5 | 1 up, 0 down | Aug 4, 2022 | $80.63M |
| Mar 31, 2022 | -$0.13 | -$0.04 | -$0.09 - -$0.01 | -225.00% | Miss | -192.9% | 5 | 0 up, 0 down | May 5, 2022 | $79.42M |
| Dec 31, 2021 | -$0.03 | $0.03 | -$0.03 - $0.08 | -200.00% | Miss | -137.5% | 4 | 0 up, 0 down | Feb 24, 2022 | $79.22M |
| Sep 30, 2021 | $0.07 | $0.02 | -$0.02 - $0.05 | +250.00% | Beat | -30.0% | 5 | N/A | Oct 28, 2021 | $75.59M |
| Jun 30, 2021 | $0.11 | $0.06 | $0.04 - $0.06 | +83.33% | Beat | +175.0% | 5 | N/A | Jul 29, 2021 | $74.19M |
| Mar 31, 2021 | $0.14 | $0.01 | -$0.05 - $0.04 | N/A | N/A | N/A | 4 | N/A | May 5, 2021 | $67.40M |
| Dec 31, 2020 | $0.08 | $0.02 | -$0.09 - $0.09 | +300.00% | Beat | +100.0% | 4 | N/A | Feb 24, 2021 | $47.08M |
| Sep 30, 2020 | $0.10 | -$0.06 | -$0.09 - -$0.01 | +266.67% | Beat | +400.0% | 3 | N/A | Oct 29, 2020 | $106.74M |
| Jun 30, 2020 | $0.04 | -$0.04 | -$0.09 - $0.03 | +200.00% | Beat | N/A | 4 | N/A | Aug 4, 2020 | N/A |
| Mar 31, 2020 | -$0.14 | $0.03 | $0.01 - $0.05 | -566.67% | Miss | -380.0% | 4 | N/A | Apr 30, 2020 | $38.38M |
| Dec 31, 2019 | $0.04 | $0.02 | -$0.02 - $0.04 | +100.00% | Beat | +300.0% | 4 | N/A | Feb 27, 2020 | $35.82M |
| Sep 30, 2019 | $0.02 | $0.01 | -$0.10 - $0.12 | +100.00% | Beat | N/A | 4 | N/A | Oct 31, 2019 | $33.81M |
| Jun 30, 2019 | -$0.19 | -$0.10 | N/A | -90.00% | Miss | N/A | 4 | N/A | Aug 1, 2019 | $31.45M |
| Mar 31, 2019 | $0.05 | -$0.04 | -$0.06 - $0.00 | +225.00% | Beat | N/A | 4 | N/A | May 8, 2019 | $25.98M |
| Dec 31, 2018 | $0.01 | -$0.09 | N/A | +111.11% | Beat | N/A | 4 | N/A | Mar 6, 2019 | $23.51M |
| Sep 30, 2018 | -$0.01 | -$0.03 | N/A | +66.67% | Beat | N/A | N/A | N/A | Nov 8, 2018 | $21.18M |
| Jun 30, 2018 | -$0.04 | -$0.07 | -$0.09 - -$0.05 | +42.86% | Beat | N/A | 2 | N/A | Aug 9, 2018 | $17.82M |
| Mar 31, 2018 | -$0.14 | -$0.13 | -$0.13 - -$0.13 | -7.69% | Miss | N/A | 1 | N/A | May 10, 2018 | $14.05M |
| Dec 31, 2017 | -$0.09 | -$0.13 | -$0.17 - -$0.11 | +30.77% | Beat | N/A | 3 | N/A | Mar 22, 2018 | $12.50M |
| Sep 30, 2017 | -$0.15 | -$0.17 | N/A | +11.76% | Beat | N/A | N/A | N/A | Nov 9, 2017 | $12.19M |
| Jun 30, 2017 | -$0.17 | -$0.20 | N/A | +15.00% | Beat | N/A | N/A | N/A | Aug 10, 2017 | $12.05M |
| Mar 31, 2017 | -$0.13 | -$0.17 | N/A | +23.53% | Beat | N/A | N/A | N/A | Apr 21, 2017 | $11.58M |
| Dec 31, 2016 | -$0.73 | -$0.18 | N/A | -305.56% | Miss | N/A | N/A | N/A | Mar 23, 2017 | $10.86M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.60, up 11.1% from the year before. It was -$1.54 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.60 | +11.1% |
| Dec 31, 2024 | $0.54 | N/A |
| Dec 31, 2023 | -$0.64 | N/A |
| Dec 31, 2022 | -$0.39 | -234.5% |
| Dec 31, 2021 | $0.29 | +262.5% |
| Dec 31, 2020 | $0.08 | N/A |
| Dec 31, 2019 | -$0.08 | N/A |
| Dec 31, 2018 | -$0.18 | N/A |
| Dec 31, 2017 | -$0.54 | N/A |
| Dec 31, 2016 | -$1.54 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,700 words across 11 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,664 | 11 | |
| 2026Q2 | Jun 30, 2026 | 5,458 | 8 | |
| 2026Q1 | Mar 31, 2026 | 7,550 | 12 | |
| 2025Q4 | Dec 31, 2025 | 9,113 | 13 | |
| 2025Q3 | Sep 30, 2025 | 6,921 | 13 | |
| 2025Q2 | Jun 30, 2025 | 4,308 | 9 | |
| 2025Q1 | Mar 31, 2025 | 6,744 | 10 | |
| 2024Q4 | Dec 31, 2024 | 5,834 | 11 |
2026Q3 Earnings Call
Opening remarks
Nina Deka Head of Investor Relations Thank you, operator. Good afternoon. Thank you for joining us today. Earlier today, CareDx released financial results for the third quarter 2026, ending September 30, 2026. The results and our earnings presentation are available on the company's website at caredx.com. Joining me on today's call are John Hanna, President and Chief Executive Officer, and Keith Kennedy, Chief Operating Officer and Chief Financial Officer. Before we get started, I would like to remind everyone that management will be making statements during this call that include forward-looking statements. Any statements contained in this call that are not statements of historical facts should be deemed to be forward-looking statements. All forward-looking statements are based upon current estimates and various assumptions. These statements involve material risks and uncertainties that can cause actual results to differ materially from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. Information concerning the risks, uncertainties, and other factors that could cause results to differ from these forward-looking statements is included in our filings with the Securities and Exchange Commission. The information provided in this conference call speaks only to the live broadcast today, October 29, 2026. We disclaim any intention or obligation, except as required by law, to update or revise any information, financial projections, or other forward-looking statements, whether because of new information, future events, or otherwise. This call will also include a discussion of certain non-GAAP financial measures. These non-GAAP financial measures should be considered in addition to, not as a substitute or in isolation from, GAAP measures. Reconciliations of our non-GAAP financial measures to the most directly comparable GAAP financial measures may be found in today's earnings release or investor presentation, which are posted on our website. With that, I will now turn the call over to John.
John Hanna President and Chief Executive Officer Thank you, Nina. Good afternoon, everyone, and thank you all for joining us today. We had another strong quarter of solid execution, extending our leadership in transplantation, expanding into specialty oncology, and preparing for our entrance into cell therapy. As a reminder, our strategy is to focus on markets where we believe our core competencies give us the right to win: markets where patients face a high burden of disease and are managed by a concentrated group of subspecialty providers, where the high cost of treatment and disease management warrants repeat molecular testing, and where our solution-selling approach, including integrated testing, digital solutions, and pharmacy, can create a competitive advantage. In my conversations with clinicians across transplantation, oncology, and cell therapy over the past quarter, the feedback is consistent.
Frequently Asked Questions About CDNA
When is CareDx's next earnings date?
CareDx's next earnings report is expected for Feb 22, 2027.
Did CDNA beat earnings estimates last quarter?
Yes. CareDx reported EPS of $0.70 for the quarter ended Sep 30, 2026, above the $0.07 estimate, a 900.00% surprise.
What EPS do analysts expect from CDNA next quarter?
The consensus EPS estimate for CareDx for the quarter ending Dec 31, 2026 is $0.37 from 10 analysts, with estimates from $0.30 to $0.43.
How often does CDNA beat earnings estimates?
CareDx beat the EPS estimate in 7 of the 8 most recent quarters that had an estimate, with an average surprise of +250.63%.
CDNA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts